Current Report Filing (8-k)
October 10 2018 - 5:17PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
October 10, 2018
(
October 8, 2018)
Heyu
Biological Technology Corporation
(Exact Name of Registrant as Specified in
its Charter)
Nevada
|
|
000-26731
|
|
87-0627910
|
(State
or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification Number)
|
4th Floor, No. 10 Building, Xinglin Bay
Business Operation Center,
Jimei District, Xiamen City,
Fujian Province, China 361022
(Address of Principal Executive Offices,
Zip Code)
Registrant’s telephone number, including
area code:
(86) 158 5924 0902
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On October 8, 2018, Heyu Biological
Technology Corporation (the “Company”) entered into a non-binding letter of intent with Fujian
Shanzhiling Biological Technology Co., Ltd (the “Acquirer”), a Chinese biotechnology product manufacturing corporation,
whereby the Acquirer agreed to acquire 51 percent (51%) of the outstanding capital of the Company subject to certain adjustment
provisions (the “Acquisition”).
The closing of the Acquisition
is subject to customary terms and conditions, including, but not limited to, completion of due diligence, negotiation and execution
of definitive transaction documents between the parties and the delivery of audited and unaudited financial statements of the Target
as required under applicable rules of the Securities and Exchange Commission. In addition, completion of the transaction is subject
to approval by our board of directors.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Company has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Heyu Biological Technology Corporation
|
|
|
|
|
By:
|
/s/
Ban Siong Ang
|
|
Name:
|
Ban Siong Ang
|
|
Title:
|
Chief Executive Officer
|
|
|
|
|
Dated:
|
October 10, 2018
|
Heyu Biological Technology (PK) (USOTC:HYBT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Heyu Biological Technology (PK) (USOTC:HYBT)
Historical Stock Chart
From Apr 2023 to Apr 2024